Related Experiment Videos
The pyruvate dehydrogenase complex as a target for gene therapy
Peter W Stacpoole1, Renius Owen, Terence R Flotte
1Department of Medicine, Division of Endocrinology and Metabolism, University of Florida, College of Medicine, Gainesville, FL 32610, USA. stacpool@gcrc.ufl.edu
Current Gene Therapy
|May 24, 2003
Summary
Gene therapy shows promise for pyruvate dehydrogenase complex (PDC) defects. Delivering the E1alpha subunit via rAAV partially restored PDC activity in patient cells, suggesting a potential treatment for mitochondrial energy disorders.
Area of Science:
- Biochemistry
- Molecular Biology
- Gene Therapy
Background:
- Pyruvate dehydrogenase complex (PDC) is crucial for cellular energy production via aerobic metabolism.
- PDC activity is regulated by phosphorylation of its E1alpha subunit.
- Congenital and acquired PDC deficiencies cause severe metabolic and neurodegenerative disorders.
Purpose of the Study:
- To review the potential of targeting the PDC for gene therapy.
- To investigate the feasibility of restoring PDC function through gene transfer.
Main Methods:
- Utilized a recombinant adeno-associated virus (rAAV) vector to deliver wild-type E1alpha.
- Injected the rAAV construct into the rat central nervous system and human cells in vitro.
- Assessed PDC activity restoration by measuring 14C-pyruvate decarboxylation in patient fibroblasts.
Main Results:
- Successful delivery of wild-type E1alpha into mitochondria.
- Partial restoration of PDC activity in fibroblasts from a patient with E1alpha deficiency.
- Demonstrated feasibility of gene transfer for correcting PDC defects.
Conclusions:
- Gene transfer is a viable strategy for partially correcting pyruvate dehydrogenase complex defects.
- Combining AAV-mediated E1alpha delivery with pharmacologic activation may offer an optimal therapeutic approach.
- This approach holds potential for treating congenital and acquired mitochondrial energy metabolism disorders.